DK1148875T3 - Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer - Google Patents
Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemerInfo
- Publication number
- DK1148875T3 DK1148875T3 DK00903441T DK00903441T DK1148875T3 DK 1148875 T3 DK1148875 T3 DK 1148875T3 DK 00903441 T DK00903441 T DK 00903441T DK 00903441 T DK00903441 T DK 00903441T DK 1148875 T3 DK1148875 T3 DK 1148875T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- increasing
- methods
- blood cells
- white blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11825599P | 1999-02-02 | 1999-02-02 | |
| PCT/CA2000/000104 WO2000045814A1 (en) | 1999-02-02 | 2000-02-02 | Methods and compositions to enhance white blood cell count |
| EP00903441A EP1148875B1 (en) | 1999-02-02 | 2000-02-02 | Methods and compositions to enhance white blood cell count |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1148875T3 true DK1148875T3 (da) | 2004-10-18 |
Family
ID=22377471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00903441T DK1148875T3 (da) | 1999-02-02 | 2000-02-02 | Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6365583B1 (da) |
| EP (1) | EP1148875B1 (da) |
| JP (2) | JP4968868B2 (da) |
| KR (1) | KR100643553B1 (da) |
| CN (1) | CN1310642C (da) |
| AP (1) | AP1497A (da) |
| AT (1) | ATE268597T1 (da) |
| AU (2) | AU772979B2 (da) |
| BR (1) | BR0007924A (da) |
| CA (1) | CA2361587C (da) |
| CZ (1) | CZ20012698A3 (da) |
| DE (1) | DE60011391T2 (da) |
| DK (1) | DK1148875T3 (da) |
| ES (1) | ES2222174T3 (da) |
| HK (1) | HK1038319B (da) |
| HU (1) | HUP0200100A3 (da) |
| IL (1) | IL144400A (da) |
| MX (1) | MXPA01007801A (da) |
| NO (1) | NO20013770L (da) |
| NZ (1) | NZ513602A (da) |
| PT (1) | PT1148875E (da) |
| SI (1) | SI1148875T1 (da) |
| TR (1) | TR200102239T2 (da) |
| WO (1) | WO2000045814A1 (da) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| EP1244648B1 (en) * | 1999-12-17 | 2009-04-15 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds |
| US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
| NZ524421A (en) * | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| NZ524651A (en) * | 2000-09-15 | 2005-08-26 | Anormed Inc | Chemokine receptor binding heterocyclic compounds for the treatment of HIV or FIV |
| PL359292A1 (en) | 2000-09-29 | 2004-08-23 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
| SI1411918T1 (sl) * | 2001-07-31 | 2012-04-30 | Genzyme Global S A R L | Postopki za mobilizacijo progenitorskih/matičnih celic |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| CN1272322C (zh) * | 2001-09-12 | 2006-08-30 | 阿诺麦德股份有限公司 | 对映体纯的氨基取代稠合双环的合成 |
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| MXPA04006136A (es) * | 2001-12-21 | 2004-11-01 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada. |
| AU2003261723A1 (en) | 2002-08-27 | 2004-03-19 | Takeda Chemical Industries, Ltd. | Cxcr4 antagonist and use thereof |
| US7291631B2 (en) * | 2003-04-11 | 2007-11-06 | Genzyme Corporation | CXCR4 chemokine receptor binding compounds |
| CN101941964A (zh) * | 2003-04-22 | 2011-01-12 | 阿诺麦德股份有限公司 | 具有促进功效的趋化因子受体结合的杂环化合物 |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| EP1708703A4 (en) * | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
| US7498346B2 (en) * | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| WO2006020891A2 (en) * | 2004-08-13 | 2006-02-23 | Anormed Inc. | Chemokine combinations to mobilize progenitor/stem cells |
| CA2612325A1 (en) * | 2005-06-15 | 2006-12-28 | Anormed Inc. | Chemokine receptor binding compounds |
| CA2619881A1 (en) * | 2005-08-16 | 2007-02-22 | Genzyme Corporation | Chemokine receptor binding compounds |
| US20100035941A1 (en) * | 2006-02-24 | 2010-02-11 | Bridger Gary J | Methods for increasing blood flow and/or promoting tissue regeneration |
| AR063470A1 (es) * | 2006-08-02 | 2009-01-28 | Genzyme Corp | Terapia combinada |
| CA2659337A1 (en) * | 2006-08-07 | 2008-02-14 | Genzyme Corporation | Combination therapy |
| US8455450B2 (en) * | 2006-12-21 | 2013-06-04 | Biokine Therapeutics Ltd. | Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof |
| US9155780B2 (en) | 2009-02-11 | 2015-10-13 | Yeda Research And Development Co. Ltd. | Short beta-defensin-derived peptides |
| ES2462517T3 (es) | 2009-06-14 | 2014-05-23 | Biokine Therapeutics Ltd. | Terapia con péptidos para aumentar los niveles de plaquetas |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| RU2638802C2 (ru) * | 2011-05-16 | 2017-12-15 | Джензим Корпорейшн | Применение антагонистов cxcr4 |
| EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
| AU2016291817A1 (en) | 2015-07-16 | 2018-02-22 | Biolinerx Ltd. | Compositions and methods for treating cancer |
| JP6864296B2 (ja) | 2015-12-14 | 2021-04-28 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がんを処置する方法 |
| EP3389652B1 (en) | 2015-12-14 | 2022-09-28 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2935834T3 (es) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Métodos para tratar enfermedad de inmunodeficiencia |
| CA3014530A1 (en) | 2016-02-23 | 2017-08-31 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
| EP3440112A4 (en) | 2016-04-08 | 2019-10-09 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CN109187337A (zh) * | 2018-09-10 | 2019-01-11 | 南京工业职业技术学院 | 一种筛选强韧性FeAl晶界的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5612478A (en) | 1995-03-30 | 1997-03-18 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| US5606053A (en) | 1995-05-02 | 1997-02-25 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| AU1732900A (en) * | 1998-11-17 | 2000-06-05 | Ligand Pharmaceuticals Incorporated | Methods of treating thrombocytopenia |
-
2000
- 2000-02-01 US US09/495,298 patent/US6365583B1/en not_active Expired - Lifetime
- 2000-02-02 PT PT00903441T patent/PT1148875E/pt unknown
- 2000-02-02 TR TR2001/02239T patent/TR200102239T2/xx unknown
- 2000-02-02 MX MXPA01007801A patent/MXPA01007801A/es not_active IP Right Cessation
- 2000-02-02 WO PCT/CA2000/000104 patent/WO2000045814A1/en active IP Right Grant
- 2000-02-02 KR KR1020017009649A patent/KR100643553B1/ko not_active IP Right Cessation
- 2000-02-02 DE DE60011391T patent/DE60011391T2/de not_active Expired - Lifetime
- 2000-02-02 AU AU25278/00A patent/AU772979B2/en not_active Ceased
- 2000-02-02 CN CNB008033285A patent/CN1310642C/zh not_active Expired - Fee Related
- 2000-02-02 SI SI200030444T patent/SI1148875T1/xx unknown
- 2000-02-02 EP EP00903441A patent/EP1148875B1/en not_active Expired - Lifetime
- 2000-02-02 HU HU0200100A patent/HUP0200100A3/hu unknown
- 2000-02-02 JP JP2000596934A patent/JP4968868B2/ja not_active Expired - Fee Related
- 2000-02-02 CA CA2361587A patent/CA2361587C/en not_active Expired - Fee Related
- 2000-02-02 NZ NZ513602A patent/NZ513602A/en unknown
- 2000-02-02 CZ CZ20012698A patent/CZ20012698A3/cs unknown
- 2000-02-02 BR BR0007924-3A patent/BR0007924A/pt not_active Application Discontinuation
- 2000-02-02 IL IL144400A patent/IL144400A/en not_active IP Right Cessation
- 2000-02-02 AP APAP/P/2001/002221A patent/AP1497A/en active
- 2000-02-02 ES ES00903441T patent/ES2222174T3/es not_active Expired - Lifetime
- 2000-02-02 DK DK00903441T patent/DK1148875T3/da active
- 2000-02-02 AT AT00903441T patent/ATE268597T1/de not_active IP Right Cessation
-
2001
- 2001-08-01 NO NO20013770A patent/NO20013770L/no not_active Application Discontinuation
-
2002
- 2002-01-04 US US10/039,150 patent/US6670354B2/en not_active Expired - Lifetime
- 2002-01-07 HK HK02100103.2A patent/HK1038319B/zh not_active IP Right Cessation
-
2004
- 2004-08-13 AU AU2004203847A patent/AU2004203847B2/en not_active Ceased
-
2011
- 2011-02-04 JP JP2011023235A patent/JP2011088937A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1148875T3 (da) | Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer | |
| NO20000011D0 (no) | Skumdempersammensetninger og fremgangsmåter | |
| DK0958838T3 (da) | Fremgangsmåde til fjernelse af hvide blodlegemer | |
| NO20013393L (no) | Bronnsementeringsfremgangsmater og sammensetninger | |
| NO20005828D0 (no) | Herdbare punktfluidsammensetninger og fremgangsmåter | |
| ATE388677T1 (de) | Zwischenwirbelimplantat | |
| DK1202941T3 (da) | Gipssammensætninger og beslægtede fremgangsmåder | |
| ATE357459T1 (de) | Antikörper gegen mensliches il-12 | |
| DK1329456T3 (da) | Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme | |
| DK1360287T3 (da) | Fremgangsmåder til modifikation af eukaryotiske celler | |
| DE50010727D1 (de) | Flächiges Implantat | |
| NO20022334L (no) | Ny sammensetning og anvendelse | |
| DK1437106T3 (da) | Prøveimplantatsæt | |
| DK1242095T3 (da) | Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK1352895T3 (da) | Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme | |
| DK0969846T3 (da) | Sammensætninger og fremgangsmåder til reduktion af okulær hypertension | |
| FR2780269B1 (fr) | Implant rachidien | |
| DK1114641T3 (da) | Fluorethersammensætninger og metoder til inhibering af deres nedbrydning i nærværelse af en Lewis-syre | |
| NO20021786D0 (no) | Skumdempningsfremgangsmåter og sammensetninger | |
| DK1150991T3 (da) | Præparater til behandling af inflammatoriske reaktioner | |
| IS2841B (is) | Samstæða hluta og lyfjasamsetningar | |
| DK1355936T3 (da) | Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme | |
| DK199800837A (da) | Anlæg til behandling af emner | |
| DK1702623T3 (da) | Anvendelse af interferon-gamma til behandling af hjertehypertrofi | |
| CU23064A3 (es) | Conjunto implante dental-transportador |